Print this page

John E. Tavis, Ph.D.

 

John E. Tavis, Ph.D.
Professor
Molecular Microbiology & Immunology
Saint Louis University School of Medicine


Education:
Ph.D., The Pennsylvania State University, 1990

Doisy Research Center
1100 South Grand Blvd
Office/Lab 613/655
Saint Louis, MO 63104

Email:tavisje@slu.edu
Office: 977-8893
Lab: 977-8894


John E. Tavis, Ph.D.

Research Summary:

Our lab studies Hepatitis B virus (HBV) and Hepatitis C virus (HCV). HBV and HCV are major causes of liver disease, including liver cancer, and together they cause nearly two millions of deaths each year world-wide. HBV is a Hepadnavirus with a DNA genome that replicates by reverse transcription using a virally-encoded reverse transcriptase. HCV is a non-vector borne Flavivirus and has a highly variable RNA genome.

Hepatitis B virus. The key enzyme in HBV replication is its reverse transcriptase. The reverse transcriptase is the main target of anti-HBV nucleoside analog drugs that are incorporated into the viral DNA and block viral replication. They are very good drugs, but they are not quite strong enough to eliminate the infection. Therefore, new drug targets that function by different mechanisms are needed to permit combination drug therapy. To identify such targets, we are studying the reverse transcriptase, using both HBV and the related animal virus, Duck Hepatitis B virus (DHBV).

We our primary focus is on the viral ribonuclease H activity that destroys the viral RNA after it has been copied into DNA.  We recently expressed the HBV RNAseH as an active recombinant protein and found that it could be inhibited by antagonists of the HIV RNAseH and integrase enzymes.  We also demonstrated for the first time that HBV viral replication could be pharmacologically inhibited using antagonists of the RNAseH.  These studies provide proof-of-concept that the HBV RNAseH is an attractive target for antiviral drug development, and we are beginning drug discovery efforts.  We also work on the mechanism by which the reverse transcriptase binds to the viral RNA that is the template for viral DNA synthesis. We identified two motifs on the enzyme that directly bind to the RNA and have begun to characterize the enzyme’s complex, two-stage RNA binding mechanism. We are extending these studies with the hope that learning how to disrupt these RNA binding interfaces will lead to a new anti-HBV drug.

Inhibition of the HBV RNAseH by β-Thujaplicionol

Figure 1. Inhibition of the HBV RNAseH by β-Thujaplicionol.  An oligonucleotide-directed RNA cleavage assay was conducted using a uniformly-labeled RNA and a complementary DNA oligo (+) or a non-complementary oligo (-) as a control.  Cutting the RNA:DNA heteroduplex substrate (S) cleaves the RNA into two products (P1 and P2).  Plotting the data reveals that β-Thujaplicinol has an IC50 of ~6 μM against the HBV RNAseH. 

 

Hepatitis C virus. HCV is very genetically variable, with six major genotypes and multiple subtypes. The genetic distance between two HCV isolates of the same subtype is larger than the difference between a typical mouse and human gene. We seek to understand how this viral genetic variation affects viral pathology and the response of HCV to antiviral therapy.

The backbone of HCV therapy is interferon alpha plus ribavirin, but this demanding therapy fails in about half of genotype 1 patients (the major genotype in the USA). We sequenced the HCV genome from 94 patients before therapy, stratified by response to the drugs. Viral genetic variability in patients where the virus was efficiently suppressed was much higher than in patients where suppression was minimal. This implies that the viruses in the patients who responded well were cleared due to the presence of many different variations that independently reduced their ability to counteract the strong interferon response induced by therapy, and that HCV in the poor responders survived because there are only a few ways to optimize activity of the viral proteins (and hence little genetic diversity). We are exploring the possibility that novel genome-wide genetic variation patterns we recently identified may provide a reliable clinical test to predict who will respond to interferon-based therapy, and are extending these concepts to other viruses.

HCV causes life-threatening illnesses such as cirrhosis or liver cancer in only about 25% of chronically-infected patients, but the reasons why some patients become seriously ill while disease in others is relatively mild are not understood. We hypothesized that this may be due to the presence of HCV genetic variants with varying degrees of virulence. We are conducting two studies to test this hypothesis. First, we sequenced 120 HCV genomes from 60 patients who had either rapid or slow progression of disease over a 3.5 year period. In the second study we asked whether there are oncogenic variants of HCV. Here, we sequenced the HCV genomes from 47 patients with or without liver cancer. In both cases the viral genetic analyses are being coupled to functional assays of the variant viral genes to provide biochemical evidence for or against virulence differences among the variants.

 

Figure 1. Select HCV genes in sequences from patients who responded well to therapy (marked) are more diverse than from the patients who responded poorly to therapy. Importantly, each of these genes can counteract the function of interferon alpha in vitro.

LAB MEMBERS

Left to right: Xiaohong Cheng, Megan Warner, Dr. John Tavis, Julia Gray,  Dr. Feng Cao

Publications

Hu, Y., Cheng, X., Cao, F., Huang, A., and Tavis J.E.
Replication by Blocking the viral Ribonuclease H activity.
Antiviral Research, in press.

Tavis, J.E., Gehring, A.J., and Hu, Y.
How further suppression of virus replication could improve current HBV treatment.
Expert Review of Anti-Infective Therapy, in press.

Tavis, J.E., Cheng, X., Hu, Y., Totten, M., Cao, F., Michailidis, E., Aurora, R., Meyers, M.J., Jacobsen, J., Parniak, M.A., and Sarafianos, S.G.
The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.
PLos Pathogens; 2013. 9:e1003125.
Pubmed Abstract link:23349632

Terrault, N.A., Dodge, J.L., Murphy, E.L., Tavis, J.E., Kiss, A., Levin, T.R., Gish, R., Busch, M., Reingold, A.L., and Alter, M.J. 
Sexual transmission of HCV among monogamous heterosexual couples:  The HCV Partners Study.
Hepatology; 2013. 9:e1003125.
Pubmed Abstract link:23175457

Schvoerer, E., Moenne-Loccoz, R., Murray, J.M., Velay, A., Turek, M., Fofana, I., Fafi-Kremer, S., Erba, A.C., Habersetzer, F., Foffoel, M., Gut, J.P., Donlin, M.D., Tavis, J.E., Zeisel, M.D., Stoll-Keller, F., and Baumert, T.F. 
Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
J. Infect. Dis.; 2013. 9:e1003125.
Pubmed Abstract link:23335805

Lara, J., Tavis, J.E.,Donlin, M.J., Lee, W., Yuan, H.J., Pearlman, B., Vaughan, G., Forbi, J., Xia, G.L., and Khudyakov, Y.
Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon. 
In Silico Biology; 2012. 11:213-224.
Pubmed Abstract link:23202423

Donlin, M.J., Szeto, B., Gohara, D.W., Aurora, R., and Tavis, J.E.
Genome-wide networks of amino acid covariances are common among viruses  .
J. Virol.; 2012. Mar; 86:3050-3063.
Pubmed Abstract link:22238298.

George, S.L., Varmaz, D., Tavis, J.E., and Chowdhury, A..
The GB virus C (GBV-C) NS3 serine protease inhibits HIV-1 replication in a CD4+ T lymphocyte cell line without decreasing HIV receptor expression..
PLoS One; 2011. Jan; 7:e30653.
Pubmed Abstract link:22292009.

Cao, F., and Tavis, J.E.
RNA elements needed for translation of the duck Hepatitis B virus polymerase via ribosomal shunting  .
J. Virol.; 2011. May; 85:6463-6352.
Pubmed Abstract link:21507974.

Cao, F., Donlin, M.J., Turner, K., Cheng, X., and Tavis, J.E.
Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy.
J. Viral Hepat; 2011. May; 18:349-357.
Pubmed Abstract link:20529202

Wagoner, J., Morishima, C., Graf, T.N., Oberlies, N.H., Teissier, E., Pecheur, E.I., Tavis, J.E., and Polyak S.J.
Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.
PLoS One; 2011. Jan; 6:e16464.
Pubmed Abstract link:21297922.

Wagoner, J., Negash, A., Kane, O.J., Martinez, L.E., Nahmias, Y., Bourne, N., Owen, D.M., Grove, J., Brimacombe, C., McKeating, J.A., Pecheur, E.-I., Graf, T.N,., Oberlies, N.H., Lohmann, V., Cao, F., Tavis, J.E., and Polyak, S.J.
Multiple effects of silymarin on the Hepatitis C virus lifecycle.
Hepatology; 2010. Jun; 51:1912-1921.
Pubmed Abstract link:20512985.

Donlin, M.J., Cannon, N.A., Aurora, R., Li, J., Wahed, A.S., Di Bisceglie, A., and Tavis, J.E.
Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.
PLoS One; 2010. Feb; 5:e9032.
Pubmed Abstract link:20140258.

Cano-Monreal, G.L., Wylie, K.M., Cao, F., Tavis, J.E., and Morrison, L.M.
Herpes simplex virus 2 UL13 protein kinase disrupts nuclear lamins.
Virology, 2009. Sep; 392:137-147.
Pubmed Abstract link:19640559.

Cannon, N.A., Donlin, M.J., Mayes, L.M., Castro, A.L., Di Bisceglie, A.M., and Tavis, J.E.
Evidence for action of ribavirin through the hepatitis C virus RNA polymerase.
J. Viral Hepat. 2009 Aug; 16:595-604.
Pubmed Abstract link:19243495.

Badtke, M.P., Khan, I., Cao, F., Hu, J., and Tavis, J.E.
An inter-domain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription.
Virology 2009 Jul 30; 390:130-138.
Pubmed Abstract link:19467554.

Dazert, E., Neumann-Haefelin, C., Bressanelli, S., Fitzmaurice, K., Kort, J., Timm, J., McKiernan, S., Kelleher, D., Gruener N., Tavis, J.E., Rosen, H., Shaw, J., Bowness, P., Blum, H.E., Klenerman P., Bartenschlager, R., and Thimme, R.
Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response.
J. Clin. Invest. 2009 Feb; 119:376-386.
Pubmed Abstract link: 19139562.

Tavis, J.E., and Badtke, M.P. (2009). Hepadnaviral Genomic Replication. Chapter 7 in Viral Genomic Replication, M. Götte, K. Raney, and C.E. Cameron, eds. Springer, New York, New York. In Press. PMCID: In Process.

Cao, F., Scougall, C.A., Jilbert, A.R., and Tavis, J.E.
€œPre-P€ is a secreted glycoprotein encoded as an N-terminal extension of the duck hepatitis B virus polymerase gene.
J. Virol. 2009 Jul 20; 83:1368-1378.
Pubmed Abstract link: 19004940.

Aurora, R., Donlin, M.J., Cannon, N.A., and Tavis, J.E. for the Virahep-C Study Group. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans.
J. Clin. Invest. 2009 Jan; 119:225-236.
Pubmed Abstract link: 19104147.

Commentary:
Oh, T.S. and Rice, C.M.
Predicting response to hepatitis C therapy.
J. Clin Invest. 2009 Jan; 119:5-7.
Pubmed Abstract link: 19104144.
 

Grants

ONGOING

R01 GM105414 (Blackard, P.I.)                                     05/02/13-04/30/18

NIH/NIGMS

Genotypic & phenotypic characterization of the HCV polymerase (NS5B) in HIV

The major goal of this grant is to determine how HIV-induced sequence changes in HCV affect function of the HCV NS5B RNA polymerase.  Dr. Tavis will conduct Aim3 of this grant, which involves purifying and biochemically evaluating a collection of variant HCV RNA polymerases.

 

No grant number yet (Tavis, P.I.)                                    06/01/13-05/31/14

Washington University Institute of Clinical and Translational Sciences

Repurposing HIV integrase drugs as HBV RNAseH inhibitors

The goal of this grant is to determine whether analogs of the HIV integrase drugs Raltegravir and Elvitegravir can inhibit the HBV RNAseH.

 

R01 CA126807 (Tavis, P.I.)                                            01/14/08 - 12/31/13

NIH/NCI

HCV genetic variation and hepatocellular carcinoma

The major goal of this project is to determine how natural sequence variation in the full-length HCV genome affects its oncogenic potential through a combination of genetic and functional analyses.

 

R01 DK080711 (Fan, P.I.)                                              03/01/08 – 02/28/14

NIH/NIDDK

Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy

The major goal of this project is to evaluate patterns of genetic variation in the full-length HCV quasispecies during antiviral therapy.

 

RECENTLY COMPLETED

 

2-30076 (Tavis, P.I.)                                                      09/01/11-02/28/13

Saint Louis University President’s Research Fund

Biochemical characterization of the HBV RNAseH as a novel drug target

The major goal of this institutional seed grant is to perform a basic biochemical characterization of recombinant Hepatitis B virus RNAseH proteins from divergent HBV genotypes in preparation for drug screening.

 

R01 DK074515 (Tavis, P.I.)                                            07/15/07 – 06/30/12

NIH/NIDDK

Role of HCV sequence variation in pathology

The major goal of this project was to determine how natural sequence variation in the full-length HCV genome affect its virulence in collaboration with the HALT-C clinical study.

3-07813 (Tavis, P.I.)                                                      01/1/10 – 02/28/11

Saint Louis University President’s Research Fund

HCV covariance networks as biomarkers of non-response to therapy

The goal of this seed grant was to provide preliminary validation in an external patient cohort of the ability of HCV amino acid covariance networks to predict non-response to interferon α- based therapy.

R43 AI84232 (Cao, P.I.)                                                08/01/09-07/31/10

An HBV polymerase RNA binding assay suitable for inhibito screening.

The major goal of this project was to identify the form of recombinant HBV reverse transrciptase best suited for use in a screen for therapeutic inhibitors of RNA binding by the enzyme.  Dr. Tavis relinquished the role of P.I. on this project to Dr. Cao when the NIAID converted the application from an R41 STTR to an R43 SBIR grant.

R01 AI057573 (Morrison, P.I.)                                    05/01/04 - 01/30/10

NIH/NIAID

Functional analysis of HSV2 tegument proteins in mice

The major goal of this project was to examine the function and contribution to pathogenesis of the HSV2 tegument proteins UL13 and VP22 in cultured cells and in mice.

R21 CA125321 (Tavis, P.I.)                                         06/07/07 – 05/31/09

NIH/NCI

Variation in NTP use by the HCV polymerase and response to therapy

The major goal of this project was to determine how natural variation in the HCV RNA polymerase affects its use of ribavirin triphosphate.

R01 AI38447 (Tavis, P.I.)                                               07/01/96 - 04/30/08

NIH/NIAID

Analysis of the hepadnaviral reverse transcriptase

The major goal of this project was to obtain a molecular understanding of the hepatitis B virus reverse transcriptase, using the duck hepatitis B virus enzyme as a model.  We studied the activity of the enzyme, its structure, and its interaction with cells.

R03 AI059050 (Morrison, P.I.)                                     03/01/05 – 02/28/08

NIH/NIAID

Substrate recognition motif of the HSV-2 UL13 kinase

The major goal of this project was to identify the substrate recognition motif of the HSV-2 UL13 protein kinase to guide subsequent efforts to determine the role of UL13 in viral replication and pathology.

No Project Number (Tavis, P.I.)                                    09/01/05 – 08/31/07

Friends of the St. Louis University Liver Center

Mechanism of ribavirin action through the HCV NS5B RNA polymerase

The goal of this project was to determine if natural variation in the HCV NS5B RNA-dependent RNA polymerase modulates incorporation of the antiviral nucleoside analog ribavirin, hence modulating its effectiveness.

U01 DK60345 (Tavis, P.I.)                                              07/01/01 - 04/30/07

NIH/NIDDK

Response of HCV to therapy in African Americans

The major goal of this project was to analyze genetic variation in HCV associated with success or failure of antiviral therapy with pegylated interferon alpha plus ribavirin in African Americans and Caucasian Americans.

 

 


Previous page: Lynda A. Morrison, Ph.D.
Next page: Ryan Teague, Ph.D.